The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer

Asian J Androl. 2016 Jul-Aug;18(4):592-3. doi: 10.4103/1008-682X.172821.

Abstract

The TOPARP study showed the beneficial utility of olaparib in a heavily pretreated population of metastatic castration-resistant prostate cancer who were biomarker-positive for aberrations in DNA repair gene. A higher response rate to olaparib of 88% (14 out of 16 patients), time to radiographic progression as well as overall survival, was seen in patients who were biomarker-positive compared to those who were not. This study showed a promising way of targeting prostate cancer with an enriched population of patients who harbor these deleterious genes. This paves the way for offering new therapeutic opportunities for men who have otherwise few remaining options.

Trial registration: ClinicalTrials.gov NCT02438007.

Publication types

  • Comment

MeSH terms

  • Enzyme Inhibitors
  • Humans
  • Male
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Poly(ADP-ribose) Polymerases*
  • Prostatic Neoplasms

Substances

  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerases

Associated data

  • ClinicalTrials.gov/NCT02438007